Relay Therapeutics Inc - Asset Resilience Ratio
Relay Therapeutics Inc (RLAY) has an Asset Resilience Ratio of 62.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Relay Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Relay Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Relay Therapeutics Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Relay Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read RLAY total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $437.48 Million | 62.53% |
| Total Liquid Assets | $437.48 Million | 62.53% |
Asset Resilience Insights
- Very High Liquidity: Relay Therapeutics Inc maintains exceptional liquid asset reserves at 62.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Relay Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Relay Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Relay Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Relay Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.72% | $470.50 Million | $621.33 Million | +0.32pp |
| 2024-12-31 | 75.41% | $657.04 Million | $871.30 Million | +3.56pp |
| 2023-12-31 | 71.84% | $606.35 Million | $843.98 Million | -5.18pp |
| 2022-12-31 | 77.03% | $847.12 Million | $1.10 Billion | +9.80pp |
| 2021-12-31 | 67.23% | $677.95 Million | $1.01 Billion | +38.42pp |
| 2020-12-31 | 28.81% | $230.41 Million | $799.83 Million | -51.04pp |
| 2019-12-31 | 79.85% | $313.86 Million | $393.07 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $428.61 Million | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more